Phosphatidylinositol 3-kinase signaling as a therapeutic target for cervical cancer

Current Cancer Drug Targets

Volumn 13, Issue 2, 2013, Pages 143-156

  Wu, Jianghong ^a,b   Chen, Chen ^c   Zhao, Kong Nan ^c,d,e  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d WENZHOU MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cervical cancer; Chemoradiosensitizers; Chemoradiotherapy; Growth factors; Notch signalings; Phytochemicals; PI3K inhibitors; PI3K AKT mTOR signalings

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL) CHROMONE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4, 6 DIMORPHOLINO 1, 3, 5 TRIAZINE; 2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; 2 MORPHOLINO 8 PHENYLCHROMONE; 3, 3' DIINDOLYLMETHANE; ARTESUNATE; CAPECITABINE; CETUXIMAB; CHEMOKINE RECEPTOR CXCR4; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLACEBO; PROTEIN S6; RAPAMYCIN; RESVERATROL; SMALL INTERFERING RNA; SOMATOMEDIN B RECEPTOR; TRASTUZUMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; APOPTOSIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; GENOMICS; HUMAN; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHYTOCHEMISTRY; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SOMATIC MUTATION; TUMOR CELL; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PHYTOTHERAPY; SIGNAL TRANSDUCTION; UTERINE CERVICAL NEOPLASMS;

EID: 84876848181     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009611313020004     Document Type: Review

References (94)

1. zur Hausen, H. Viruses in human cancers. Science 1991, 254 (5035), 1167-1173.
2. Zhao, K. N.; Chen, J. Codon usage roles in human papillomavirus. Rev. Med. Virol. 2011, 21 (6), 397-411.
3. Van Doorslaer, K.; Burk, R. D. Evolution of human papillomavirus carcinogenicity. Adv. Virus. Res. 2010, 77, 41-62.
4. Kulski, J. K.; Howard, M. J.; Pixley, E. C. DNA sequences of human papillomavirus types 11, 16 or 18 in invasive cervical carcinoma of western australian women. Immunol. Cell Biol. 1987, 65 (Pt 1), 77-84.
5. McAuliffe, P. F.; Meric-Bernstam, F.; Mills, G. B.; Gonzalez-Angulo, A. M. Deciphering the role of pi3k/akt/mtor pathway in breast cancer biology and pathogenesis. Clin. Breast. Cancer 2010, 10, Suppl 3, S59-65.
6. Lee, C. M.; Fuhrman, C. B.; Planelles, V.; Peltier, M. R.; Gaffney, D. K.; Soisson, A. P.; Dodson, M. K.; Tolley, H. D.; Green, C. L.; Zempolich, K. A. Phosphatidylinositol 3-kinase inhibition by ly294002 radiosensitizes human cervical cancer cell lines. Clin. Cancer Res. 2006, 12 (1), 250-256.
7. Ma, Y. Y.; Wei, S. J.; Lin, Y. C.; Lung, J. C.; Chang, T. C.; Whang-Peng, J.; Liu, J. M.; Yang, D. M.; Yang, W. K.; Shen, C. Y. Pik3ca as an oncogene in cervical cancer. Oncogene 2000, 19 (23), 2739-2744.
8. Cui, B.; Zheng, B.; Zhang, X.; Stendahl, U.; Andersson, S.; Wallin, K. L. Mutation of pik3ca, Possible risk factor for cervical carcinogenesis in older women. Int. J. Oncol. 2009, 34 (2), 409-416.
9. Janku, F.; Lee, J. J.; Tsimberidou, A. M.; Hong, D. S.; Naing, A.; Falchook, G. S.; Fu, S.; Luthra, R.; Garrido-Laguna, I.; Kurzrock, R. Pik3ca mutations frequently coexist with ras and braf mutations in patients with advanced cancers. PLoS One 2011, 6 (7), e22769.
10. Bertelsen, B. I.; Steine, S. J.; Sandvei, R.; Molven, A.; Laerum, O. D. Molecular analysis of the pi3k-akt pathway in uterine cervical neoplasia, Frequent pik3ca amplification and akt phosphorylation. Int. J. Cancer 2006, 118 (8), 1877-1883.
11. Eijsink, J. J.; Noordhuis, M. G.; ten Hoor, K. A.; Kok, M.; Hollema, H.; de Bock, G. H.; Nijman, H. W.; Schuuring, E.; Wisman, G. B.; van der Zee, A.G. The epidermal growth factor receptor pathway in relation to pelvic lymph node metastasis and survival in early-stage cervical cancer. Hum. Pathol. 2010, 41 (12), 1735-1741.
12. Sotiropoulou, N.; Bravou, V.; Kounelis, S.; Damaskou, V.; Papaspirou, E.; Papadaki, H. Tumour expression of lymphangiogenic growth factors but not lymphatic vessel density is implicated in human cervical cancer progression. Pathology 2010, 42 (7), 629-636.
13. Huang, Y. F.; Shen, M. R.; Hsu, K. F.; Cheng, Y. M.; Chou, C. Y. Clinical implications of insulin-like growth factor 1 system in early-stage cervical cancer. Br. J. Cancer 2008, 99 (7), 1096-1102.
14. Tang, X.; Zhang, Q.; Nishitani, J.; Brown, J.; Shi, S.; Le, A. D. Overexpression of human papillomavirus type 16 oncoproteins enhances hypoxia-inducible factor 1 alpha protein accumulation and vascular endothelial growth factor expression in human cervical carcinoma cells. Clin. Cancer Res. 2007, 13 (9), 2568-2576.
15. Shen, M. R.; Lin, A. C.; Hsu, Y. M.; Chang, T. J.; Tang, M. J.; Alper, S. L.; Ellory, J. C.; Chou, C. Y. Insulin-like growth factor 1 stimulates kcl cotransport; which is necessary for invasion and proliferation of cervical cancer and ovarian cancer cells. J. Biol. Chem. 2004, 279 (38), 40017-40025.
16. Shen, M. R.; Hsu, Y. M.; Hsu, K. F.; Chen, Y. F.; Tang, M. J.; Chou, C. Y. Insulin-like growth factor 1 is a potent stimulator of cervical cancer cell invasiveness and proliferation that is modulated by alphavbeta3 integrin signaling. Carcinogenesis 2006, 27 (5), 962-971.
17. Zhang, S.; Wu, X.; Jiang, T.; Lu, Y.; Ma, L.; Liang, M.; Sun, X., The up-regulation of kcc1 gene expression in cervical cancer cells by igf-ii through the erk1/2mapk and pi3k/akt pathways and its significance. Eur. J. Gynaecol. Oncol. 2009, 30 (1), 29-34.
18. Serrano, M. L.; Sanchez-Gomez, M.; Bravo, M. M.; Yakar, S.; LeRoith, D. Differential expression of igf-i and insulin receptor isoforms in hpv positive and negative human cervical cancer cell lines. Horm. Metab. Res. 2008, 40 (10), 661-667.
19. Majka, M.; Drukala, J.; Lesko, E.; Wysoczynski, M.; Jenson, A. B.; Ratajczak, M. Z. Sdf-1 alone and in co-operation with hgf regulates biology of human cervical carcinoma cells. Folia Histochem. Cytobiol. 2006, 44 (3), 155-164.
20. Yang, Y. C.; Lee, Z. Y.; Wu, C. C.; Chen, T. C.; Chang, C. L.; Chen, C. P. Cxcr4 expression is associated with pelvic lymph node metastasis in cervical adenocarcinoma. Int. J. Gynecol. Cancer 2007, 17 (3), 676-686.
21. Chen, R. J.; Chen, S. U.; Chou, C. H.; Lin, M. C. Lysophosphatidic acid receptor 2/3-mediated il-8-dependent angiogenesis in cervical cancer cells. Int. J. Cancer 2012, 131 (4), 789-802.
22. Maliekal, T. T.; Bajaj, J.; Giri, V.; Subramanyam, D.; Krishna, S. The role of notch signaling in human cervical cancer, Implications for solid tumors. Oncogene 2008, 27 (38), 5110-5114.
23. Ramdass, B.; Maliekal, T. T.; Lakshmi, S.; Rehman, M.; Rema, P.; Nair, P.; Mukherjee, G.; Reddy, B. K.; Krishna, S.; Radhakrishna, P. M. Coexpression of notch1 and nf-kappab signaling pathway components in human cervical cancer progression. Gynecol. Oncol. 2007, 104 (2), 352-361.
24. Veeraraghavalu, K.; Subbaiah, V. K.; Srivastava, S.; Chakrabarti, O.; Syal, R.; Krishna, S. Complementation of human papillomavirus type 16 e6 and e7 by jagged1-specific notch1-phosphatidylinositol 3-kinase signaling involves pleiotropic oncogenic functions independent of cbf1;su(h);lag-1 activation. J. Virol. 2005, 79 (12), 7889-7898.
25. Hancock, M. K.; Kopp, L.; Bi, K. High-throughput screening compatible cell-based assay for interrogating activated notch signaling. Assay Drug Dev. Technol. 2009, 7 (1), 68-79.
26. Faried, L. S.; Faried, A.; Kanuma, T.; Sano, T.; Nakazato, T.; Tamura T.; Kuwano, H.; Minegishi, T. Predictive and prognostic role of activated mammalian target of rapamycin in cervical cancer treated with cisplatin-based neoadjuvant chemotherapy. Oncol. Rep. 2006, 16 (1), 57-63.
27. Feng, W.; Duan, X.; Liu, J.; Xiao, J.; Brown, R. E. Morphoproteomic evidence of constitutively activated and overexpressed mtor pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions. Int. J. Clin. Exp. Pathol. 2009, 2 (3), 249-260.
28. Yashar, C. M.; Spanos, W. J.; Taylor, D. D.; Gercel-Taylor, C. Potentiation of the radiation effect with genistein in cervical cancer cells. Gynecol. Oncol. 2005, 99 (1), 199-205.
29. Rose, P. G. Chemoradiotherapy for cervical cancer. Eur. J. Cancer 2002, 38 (2), 270-278.
30. Kim, J.; Kim, P. H.; Yoo, J. Y.; Yoon, A. R.; Choi, H. J.; Seong, J.; Kim, I. W.; Kim, J. H.; Yun, C. O. Double e1b 19 kda-and e1b 55 kda-deleted oncolytic adenovirus in combination with radiotherapy elicits an enhanced anti-tumor effect. Gene Ther. 2009, 16 (9), 1111-1121.
31. Noordhuis, M. G.; Eijsink, J. J.; Ten, H. K. A.; Roossink, F.; Hollema, H.; Arts, H. J.; Pras E.; Maduro, J. H.; Reyners, A. K.; de Bock, G. H.; Wisman, G. B.; Schuuing, E.; van, der Zee, A. C. Expression of epidermal growth factor receptor (egfr) and activated egfr predict poor response to (chemo)radiation and survival in cervical cancer. Clin. Cancer Res. 2009, 15 (23), 7389-7397.
32. Noordhuis, M. G.; Eijsink, J. J.; Roossink, F.; de Graeff, P.; Pras, E.; Schuuring, E.; Wisman, G. B.; de Bock, G. H.; van der Zee, A. G. Prognostic cell biological markers in cervical cancer patients primarily treated with (chemo)radiation: A systematic review. Int. J. Radiat. Oncol. Biol. Phys. 2011, 79 (2), 325-334.
33. Lee, C. M.; Shrieve, D. C.; Zempolich, K. A.; Lee, R. J.; Hammond, E.; Handrahan, D. L.; Gaffney, D. K. Correlation between human epidermal growth factor receptor family (egfr, her2, her3, her4); phosphorylated akt (p-akt); and clinical outcomes after radiation therapy in carcinoma of the cervix. Gynecol. Oncol. 2005, 99 (2), 415-421.
34. Benavente, S.; Verges, R.; Hermosilla, E.; Fumanal, V.; Casanova, N.; Garcia, A.; Ramon Y Cajal, S.; Giralt, J. Overexpression of phosphorylated 4e-bp1 predicts for tumor recurrence and reduced survival in cervical carcinoma treated with postoperative radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2009, 75 (5), 1316-1322.
35. Schwarz, J. K.; Payton, J. E.; Rashmi, R.; Xiang, T.; Jia, Y.; Huettner, P.; Rogers, B. E.; Yang, Q.; Watson, M.; Rader, J. S.; Grigsby, P. W. Pathway-specific analysis of gene expression data identifies the pi3k/akt pathway as a novel therapeutic target in cervical cancer. Clin. Cancer Res. 2012, 18 (5), 1464-1471.
36. Anandharaj, A.; Cinghu, S.; Kim, W. D.; Yu, J. R.; Park, W. Y. Fused toes homolog modulates radiation cytotoxicity in uterine cervical cancer cells. Mol. Biol. Rep. 2011, 38 (8), 5361-5370.
37. Xiang, S.; Sun, Z.; He, Q.; Yan, F.; Wang, Y.; Zhang, J. Aspirin inhibits erbb2 to induce apoptosis in cervical cancer cells. Med. Oncol. 2010, 27 (2), 379-387.
38. Dan, S.; Yoshimi, H.; Okamura, M.; Mukai, Y.; Yamori, T. Inhibition of pi3k by zstk474 suppressed tumor growth not via apoptosis but g0/g1 arrest. Biochem. Biophys. Res. Commun. 2009, 379 (1), 104-109.
39. Dan, S.; Okamura, M.; Mukai, Y.; Yoshimi, H.; Inoue, Y.; Hanyu, A.; Sakaue-Sawano, A.; Imamura, T.; Miyawaki, A.; Yamori, T. Zstk474, a specific phosphatidylinositol 3-kinase inhibitor; induces g1 arrest of the cell cycle in vivo. Eur. J. Cancer 2012, 48 (6), 936-943.
40. Kim, J. H.; Kang, J. W.; Kim, M. S.; Bak, Y.; Park, Y. S.; Jung, K. Y.; Lim, Y. H.; Yoon, D. Y. The apoptotic effects of the flavonoid n101-2 in human cervical cancer cells. Toxicol. In Vitro 2012, 26 (1), 67-73.
41. Kim, M. J.; Choi, S. Y.; Park, I. C.; Hwang, S. G.; Kim, C.; Choi, Y. H.; Kim, H.; Lee, K. H.; Lee, S. J. Opposing roles of c-jun nh2-terminal kinase and p38 mitogen-activated protein kinase in the cellular response to ionizing radiation in human cervical cancer cells. Mol. Cancer Res. 2008, 6 (11), 1718-1731.
42. Castanon, A.; Tristram, A.; Mesher, D.; Powell, N.; Beer, H.; Ashman, S.; Rieck, G.; Fielder, H.; Fiander, A.; Sasieni, P. Effect of diindolylmethane supplementation on low-grade cervical cytological abnormalities: Double-blind, randomised, controlled trial. Br. J. Cancer 2012, 106 (1), 45-52.
43. Zhu, J.; Li, Y.; Guan, C.; Chen, Z. Anti-proliferative and proapoptotic effects of 3,3'-diindolylmethane in human cervical cancer cells. Oncol. Rep. 2012, 28 (3), 1063-1068.
44. Katsumata, N.; Hirai, Y.; Kamiura, S.; Sugiyama, T.; Kokawa, K.; Hatae, M.; Nishimura, R.; Ochiai, K. Phase II study of s-1: an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer. Ann. Oncol. 2011, 22 (6), 1353-1357.
45. Lamont, E. B.; Schilsky, R. L. The oral fluoropyrimidines in cancer chemotherapy. Clin. Cancer Res. 1999, 5 (9), 2289-2296.
46. Errihani, H.; M'Rabti, H.; Ismaili, N.; Inrhaoun, H.; Elghissassi, I., Phase II trial of capecitabine and cisplatin in advanced, persistent, or recurrent carcinoma of the cervix. Int. J. Gynecol. Cancer 2011, 21 (2), 373-377.
47. Ji, J.; Zheng, P. S. Activation of mtor signaling pathway contributes to survival of cervical cancer cells. Gynecol. Oncol. 2010, 117 (1), 103-108.
48. Janku, F.; Wheler J. J.; Westin, S. N.; Moulder, S. L.; Naing, A.; Tsimberidou, A. M.; Fu S.; Falchook, G. S.; Hong, D. S.; Garrido-Laguna, I; Luthra, R.; Garrido-Laguna, I.; Kurzrock, R. Pi3k/akt/mtor inhibitors in patients with breast and gynecologic malignancies harboring pik3ca mutations. J. Clin. Oncol. 2012, 30 (8), 777-782.
49. Zhang, X. Y.; Zhang, H. Y.; Zhang, P. N.; Lu, X.; Sun, H. Elevated phosphatidylinositol 3-kinase activation and its clinicopathological significance in cervical cancer. Eur. J. Obstet. Gynecol. Reprod. Biol. 2008, 139 (2), 237-244.
50. Bae-Jump, V. L.; Zhou, C.; Gehrig, P. A.; Whang, Y. E.; Boggess, J. F. Rapamycin inhibits htert telomerase mrna expression; independent of cell cycle arrest. Gynecol. Oncol. 2006, 100 (3), 487-494.
51. Saxena, A.; Yashar, C.; Taylor, D. D.; Gercel,-Taylor, C. Cellular response to chemotherapy and radiation in cervical cancer. Am. J. Obstet. Gynecol. 2005, 192 (5), 1399-1403.
52. Xia, S.; Zhao, Y.; Yu, S.; Zhang, M. Activated pi3k/akt/cox-2 pathway induces resistance to radiation in human cervical cancer hela cells. Cancer Biother. Radiopharm. 2010, 25 (3), 317-323.
53. Kim, T. J.; Lee, J. W.; Song, S. Y.; Choi, J. J.; Choi, C. H.; Kim, B. G.; Lee, J. H.; Bae, D. S. Increased expression of pakt is associated with radiation resistance in cervical cancer. Br. J. Cancer 2006, 94 (11), 1678-1682.
54. Thanaketpaisarn, O.; Waiwut, P.; Sakurai, H.; Saiki, I. Artesunate enhances trail-induced apoptosis in human cervical carcinoma cells through inhibition of the nf-kappab and pi3k/akt signaling pathways. Int. J. Oncol. 2011, 39 (1), 279-285.
55. Grisendi, G.; Bussolari, R.; Cafarelli, L.; Petak, I.; Rasini, V.; Veronesi, E.; De, S. G.; Spano, C.; Tagliazzucchi, M.; Barti-Juhasz, H.; Scarabelli, L.; Frassoldati, A.; Rossi, G.; Casali, C.; Morandi, U.; Horwitz, E.; M. Paolucci, P.; Conte, P.; Dominici, M. Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res. 2010, 70 (9), 3718-3729.
56. Wang, H.; Song, X.; Zhang, H.; Zhang, J.; Shen, X.; Zhou, Y.; Fan, X.; Dai, L.; Qian, G.; Hoffman, A. R.; Hu, J. F.; Ge, S. Potentiation of tumor radiotherapy by a radiation-inducible oncolytic and oncoapoptotic adenovirus in cervical cancer xenografts. Int. J. Cancer 2012, 130 (2), 443-453.
57. Meira, D. D.; de Almeida, V. H.; Mororo, J. S.; Nobrega, I.; Bardella, L.; Silva, R. L.; Albano, R. M.; Ferreira, C. G. Combination of cetuximab with chemoradiation, trastuzumab or mapk inhibitors: Mechanisms of sensitisation of cervical cancer cells. Br. J. Cancer 2009, 101 (5), 782-791.
58. Sandoval, M.; Morales, M.; Tapia, R.; del C, A. L.; Sordo, M.; Ostrosky-Wegman, P.; Ortega, A.; Lopez-Bayghen, E. P53 response to arsenic exposure in epithelial cells, Protein kinase b/akt involvement. Toxicol. Sci. 2007, 99 (1), 126-140.
59. Wang, X.; Ren, J. H.; Lin, F.; Wei, J. X.; Long, M.; Yan, L.; Zhang, H. Z. Stathmin is involved in arsenic trioxide-induced apoptosis in human cervical cancer cell lines via pi3k linked signal pathway. Cancer Biol. Ther. 2010, 10 (6),632-643.
60. Wang, H.; Khor, T. O.; Shu, L.; Su, Z.; Fuentes, F.; Lee, J. H.; Kong, A. N. Plants against cancer: A review on natural phytochemicals in preventing and treating cancers and their drug ability. Anticancer Agents Med. Chem. 2012.
61. Jin, L.; Qi, M.; Chen, D.Z.; Anderson, A.; Yang, G. Y.; Arbeit, J. M.; Auborn, K. J. Indole-3-carbinol prevents cervical cancer in human papilloma virus type 16 (hpv16) transgenic mice. Cancer Res. 1999, 59 (16), 3991-3997.
62. Bava, S. V.; Puliappadamba, V. T.; Deepti, A.; Nair, A.; Karunagaran, D.; Anto, R. J. Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factorkappab and the serine/threonine kinase akt and is independent of tubulin polymerization. J. Biol. Chem. 2005, 280 (8), 6301-6308.
63. Sreekanth, C. N.; Bava, S. V.; Sreekumar, E.; Anto, R. J. Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer. Oncogene 2011, 30 (28), 3139-3152.
64. Martinez-Monge, R.; Gaztanaga, M.; Aramendia, J. M.; Cambeiro, M.; Arbea, L.; Espinos, J.; Aristu, J. J.; Jurado, M. A phase II trial of less than 7 weeks of concomitant cisplatin-paclitaxel chemoradiation in locally advanced cervical cancer. Int. J. Gynecol. Cancer 2010, 20 (1), 133-140.
65. Lee, S.; Kim, H.; Kang, J. W.; Kim, J. H.; Lee, D. H.; Kim, M. S.; Yang, Y.; Woo, E. R.; Kim, Y. M.; Hong, J.; Yoon, D. Y. The biflavonoid amentoflavone induces apoptosis via suppressing e7 expression; cell cycle arrest at sub-g(1) phase, and mitochondriaemanated intrinsic pathways in human cervical cancer cells. J. Med. Food 2011, 14 (7-8), 808-816.
66. Jeong, J. H.; Jeong, Y. J.; Cho, H. J.; Shin, J. M.; Kang, J. H.; Park, K. K.; Park, Y. Y.; Chung, I. K.; Chang, H. W.; Magae, J. Ascochlorin inhibits growth factor-induced hif-1alpha activation and tumor-angiogenesis through the suppression of egfr/erk/p70s6k signaling pathway in human cervical carcinoma cells. J. Cell Biochem. 2012, 113 (4), 1302-1313.
67. Luo, T.; Yu, J.; Nguyen, J.; Wang, C. R.; Bristow, R. G.; Jaffray, D. A.; Zhou, X. Z.; Lu, K. P.; Lu, Q. B. Electron transfer-based combination therapy of cisplatin with tetramethyl-pphenylenediamine for ovarian, cervical, and lung cancers. Proc. Natl. Acad. Sci. U. S. A. 2012, 109 (26), 10175-10180.
68. Faried, L. S.; Faried, A.; Kanuma, T.; Aoki, H.; Sano, T.; Nakazato, T.; Tamura, T.; Kuwano, H.; Minegishi, T. Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix, A potential biomarker and molecular target therapy. Mol. Carcinog. 2008, 47 (6), 446-457.
69. Javvadi, P.; Segan, A. T.; Tuttle, S. W.; Koumenis, C. The chemopreventive agent curcumin is a potent radiosensitizer of human cervical tumor cells via increased reactive oxygen species production and overactivation of the mitogen-activated protein kinase pathway. Mol. Pharmacol. 2008, 73 (5), 1491-1501.
70. Kim, M. J.; Lee, T. H.; Kim, S. H.; Choi, Y. J.; Heo, J.; Kim, Y. H. Triptolide inactivates akt and induces caspase-dependent death in cervical cancer cells via the mitochondrial pathway. Int. J. Oncol. 2010, 37 (5),1177-1185.
71. Zhang, Q.; Tang, X.; Lu, Q.; Zhang, Z.; Rao, J.; Le, A. D. Green tea extract and (-)-epigallocatechin-3-gallate inhibit hypoxia-and serum-induced hif-1alpha protein accumulation and vegf expression in human cervical carcinoma and hepatoma cells. Mol. Cancer Ther. 2006, 5 (5), 1227-1238.
72. Hu, H. Z.; Yang, Y. B.; Xu, X. D.; Shen, H. W.; Shu, Y. M.; Ren, Z.; Li, X. M.; Shen, H. M.; Zeng, H. T. Oridonin induces apoptosis via pi3k/akt pathway in cervical carcinoma hela cell line. Acta Pharmacol. Sin. 2007, 28 (11), 1819-1826.
73. Garcia-Maceira, P.; Mateo, J. Silibinin inhibits hypoxia-inducible factor-1alpha and mtor/p70s6k/4e-bp1 signalling pathway in human cervical and hepatoma cancer cells, Implications for anticancer therapy. Oncogene 2009, 28 (3), 313-324.
74. Yu, H. C.; Chen, L. J.; Cheng, K. C.; Li, Y. X.; Yeh, C. H.; Cheng, J. T. Silymarin inhibits cervical cancer cell through an increase of phosphatase and tensin homolog. Phytother. Res. 2012, 26 (5), 709-715.
75. Aggarwal, B. B.; Bhardwaj, A.; Aggarwal, R. S.; Seeram, N. P.; Shishodia, S.; Takada, Y. Role of resveratrol in prevention and therapy of cancer, Preclinical and clinical studies. Anticancer Res. 2004, 24 (5A), 2783-2840.
76. Faried, A.; Faried, L. S.; Kimura, H.; Nakajima, M.; Sohda, M.; Miyazaki, T.; Kato, H.; Usman, N.; Kuwano, H. Rhoa and rhoc proteins promote both cell proliferation and cell invasion of human oesophageal squamous cell carcinoma cell lines in vitro and in vivo. Eur. J. Cancer 2006 42 (10), 1455-1465.
77. Yim, E. K.; Tong, S. Y.; Ho, E. M.; Bae, J. H.; Um, S. J.; Park, J. S. Anticancer effects on tacc3 by treatment of paclitaxel in hpv-18 positive cervical carcinoma cells. Oncol. Rep. 2009, 21 (2), 549-557.
78. Bhushan, S.; Malik, F.; Kumar, A.; Isher, H. K.; Kaur, I. P.; Taneja, S. C.; Singh, J. Activation of p53/p21/puma alliance and disruption of pi-3/akt in multimodal targeting of apoptotic signaling cascades in cervical cancer cells by a pentacyclic triterpenediol from boswellia serrata. Mol. Carcinog. 2009, 48 (12), 1093-1108.
79. Singh, M.; Singh, R.; Bhui, K.; Tyagi, S.; Mahmood, Z.; Shukla, Y. Tea polyphenols induce apoptosis through mitochondrial pathway and by inhibiting nuclear factor-kappab and akt activation in human cervical cancer cells. Oncol. Res. 2011, 19 (6), 245-257.
80. Lim, C. B.; Ky, N.; Ng, H. M.; Hamza, M. S.; Zhao, Y. Curcuma wenyujin extract induces apoptosis and inhibits proliferation of human cervical cancer cells in vitro and in vivo. Integr. Cancer Ther. 2010, 9 (1), 36-49.
81. Shin, S. Y.; Yong, Y.; Kim, C. G.; Lee, Y. H.; Lim, Y. Deoxypodophyllotoxin induces g2/m cell cycle arrest and apoptosis in hela cells. Cancer Lett. 2010, 287 (2), 231-239.
82. Sah, J. F.; Balasubramanian, S.; Eckert, R. L.; Rorke, E. A. Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of erk1/2 and akt kinases. J. Biol. Chem. 2004, 279 (13), 12755-12762.
83. Mabuchi, S.; Morishige, K.; Enomoto, T.; Kimura, T. Carboplatin and paclitaxel as an initial treatment in patients with stage ivb cervical cancer, A report of 7 cases and a review of the literature. J. Gynecol. Oncol. 2010, 21 (2), 93-96.
84. Davidson, S. Treatment for advanced cervical cancer, Impact on quality of life. Crit. Rev. Oncol. Hematol. 2011, 79 (1), 24-30.
85. Liu, B.; Fang, M.; Lu, Y.; Lu, Y.; Mills, G. B.; Fan, Z. Involvement of jnk-mediated pathway in egf-mediated protection against paclitaxel-induced apoptosis in siha human cervical cancer cells. Br. J. Cancer 2001, 85 (2), 303-311.
86. Ebert, A. D.; Wechselberger, C.; Frank, S.; Wallace-Jones, B.; Seno, M.; Martinez-Lacaci, I.; Bianco, C.; De, S. M.; Weitzel, H. K.; Salomon, D. S. Cripto-1 induces phosphatidylinositol 3'-kinasedependent phosphorylation of akt and glycogen synthase kinase 3beta in human cervical carcinoma cells. Cancer Res. 1999, 59 (18), 4502-4505.
87. Khan, S.; Chib, R.; Shah, B. A.; Wani, Z. A.; Dhar, N.; Mondhe, D. M.; Lattoo, S.; Jain, S. K.; Taneja, S. C.; Singh, J. A cyano analogue of boswellic acid induces crosstalk between p53/puma/bax and telomerase that stages the human papillomavirus type 18 positive hela cells to apoptotic death. Eur. J. Pharmacol. 2011, 660 (2-3),241-248.
88. Kim, S. H.; Kim, S. H.; Kim, Y. B.; Jeon, Y. T.; Lee, S. C.; Song, Y. S. Genistein inhibits cell growth by modulating various mitogen-activated protein kinases and akt in cervical cancer cells. Ann. N. Y. Acad. Sci. 2009, 1171, 495-500.
89. Goel, A.; Jhurani, S.; Aggarwal, B. B. Multi-targeted therapy by curcumin, How spicy is it? Mol. Nutr. Food Res. 2008, 52(9), 1010-1030.
90. Faried, L. S.; Faried, A.; Kanuma, T.; Nakazato, T.; Tamura, T.; Kuwano, H.; Minegishi, T. Inhibition of the mammalian target of rapamycin (mtor) by rapamycin increases chemosensitivity of caski cells to paclitaxel. Eur. J. Cancer 2006, 42(7), 934-947.
91. Park, J. K.; Cho, C. H.; Ramachandran, S.; Shin, S. J.; Kwon, S. H.; Kwon, S. Y.; Cha, S. D. Augmentation of sodium butyrateinduced apoptosis by phosphatidylinositol 3-kinase inhibition in the human cervical cancer cell-line. Cancer Res. Treat. 2006, 38 (2), 112-117.
92. Bava, S. V.; Sreekanth, C. N.; Thulasidasan, A. K.; Anto, N. P.; Cheriyan, V. T.; Puliyappadamba, V. T.; Menon, S. G.; Ravichandran, S. D.; Anto, R. J. Akt is upstream and mapks are downstream of nf-kappab in paclitaxel-induced survival signaling events; which are down-regulated by curcumin contributing to their synergism. Int. J. Biochem. Cell Biol. 2011, 43 (3), 331-341.
93. Fuhrman, C. B.; Kilgore, J.; LaCoursiere, Y. D.; Lee, C. M.; Milash, B. A.; Soisson, A. P.; Zempolich, K. A. Radiosensitization of cervical cancer cells via double-strand DNA break repair inhibition. Gynecol. Oncol. 2008, 110 (1), 93-98.
94. Liu, Y.; Cui, B.; Qiao, Y.; Zhang, Y.; Tian, Y.; Jiang, J.; Ma, D.; Kong, B. Phosphoinositide-3-kinase inhibition enhances radiosensitization of cervical cancer in vivo. Int. J. Gynecol. Cancer 2011, 21 (1), 100-105.